Experimental therapy in Hodgkin's disease.
Hodgkin/Reed-Sternberg (H-RS) cells express lymphoid activation markers like CD25 and CD30 which are present only on a small minority of normal cells. Currently, most experimental approaches in Hodgkin's lymphoma are aimed at targeting H-RS cells via monoclonal antibodies against CD25 and CD30: immunotoxins constructed by linking the antibody moiety chemically to deglycosylated ricin A-chain destroy up to 60% of small H-RS tumors in mice. The most potent immunotoxin is currently being scaled up for clinical trials. Other experimental strategies use bispecific constructs that, after binding to the cell surface of H-RS cells, convert prodrugs into their toxic counterparts, or employ monoclonal antibodies for active immunotherapy.
Engert
A
A
Medizinische Universitätsklinik I, Universität zu Köln, Germany.
Pohl
C
C
Diehl
V
V
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors / Q000276:immunology; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D003429:Cross Reactions; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy*; D016233:Immunotherapy, Active / Q000379:methods; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use; D017730:Ki-1 Antigen; D051379:Mice; D011355:Prodrugs / Q000627:therapeutic use; D012276:Ricin / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000922:Immunotoxins; D017730:Ki-1 Antigen; D011355:Prodrugs; D012276:Ricin; D000469:Alkaline Phosphatase